The metabolic syndrome in type 2 diabetes: When does it matter?

Aims: Young adults with type 2 diabetes (T2D m ) present the clinician with the problem of when to start therapies for the primary prevention of vascular disease and how to identify those at most vascular risk. We examine whether the metabolic syndrome (MetS) can be a useful clinical tool to stratify vascular risk in this context. Methods: Data were collected from 5928 subjects with T2D m , and subjects were categorized as having MetS by World...